InMed Pharmaceuticals Inc. (NASDAQ: INM) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT INMED PHARMACEUTICALS INC.

InMed Pharmaceuticals Inc. (NASDAQ: INM)
Listen to this Section


$1.53
-0.0550 ( -3.48% ) 26.0K

InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.

Market Data


Open $1.53
Previous Close $1.58
Volume 26.0K
Market Cap $5.24M
Day Range $1.49 - $1.58
52 Week Range $0.58 - $5.50
Shares Outstanding 3.31M
Change % -3.48%
Net Change ▼ -0.0550
Insider Ownership 0.00%
Exchange NASDAQ
SectorHealthcare
IndustryBiotechnology: Pharmaceutical Preparations
IPO Year2020
CountryCanada
UnderwriterIPO Intelligence Only

Insider Ownership Transactions

Total Amount Purchased: -314,750.00

Date Type Amount Purchased Purchaser
2024-08-02 Sale -240.00 MANCINI ALEXANDRA DIANE JANET
2024-05-28 Sale -1139.00 ADAMS ERIC A
2024-05-28 Sale -545.00 HSU ERIC C
2024-05-28 Sale -485.00 MANCINI ALEXANDRA DIANE JANET
2024-05-28 Sale -394.00 WOUDENBERG MICHAEL
2024-03-05 Sale -121.00 MANCINI ALEXANDRA DIANE JANET
2024-03-05 Sale -309.00 HSU ERIC C
2024-03-05 Sale -42.00 HULL ANDREW
2024-02-22 Buy 37500.00 HULL ANDREW
2024-02-21 Buy 41600.00 ADAMS ERIC A

SEC Filings


Form Type Description Pages Date
10-q Quarterly Reports 67 Nov 06, 2025
def Proxies and info statements 16 Nov 03, 2025
10-k/a Quarterly Reports 16 Oct 24, 2025
pre Proxies and info statements 3 Oct 24, 2025
3 Insider transactions 2 Oct 23, 2025
4 Insider transactions 1 Oct 21, 2025
3 Insider transactions 1 Oct 17, 2025
8-k 8K-related 14 Oct 16, 2025
8-k 8K-related 14 Oct 14, 2025
8-k 8K-related 15 Oct 14, 2025

Latest News


× Before browsing our site, please accept our cookies policy